Eos Energy Enterprises Inc vs uniQure N.V. Ordinary Shares — how do they compare? Eos Energy Enterprises Inc trades at $1.9 (market cap $708.31M), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.45B). The key difference: uniQure N.V. Ordinary Shares is far larger — about 2× Eos Energy Enterprises Inc's market cap, and uniQure N.V. Ordinary Shares is trading nearer its 52-week high, Eos Energy Enterprises Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Eos Energy Enterprises Inc for 17 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| EOSE | QURE | |
|---|---|---|
Market Cap | $708.31M | $1.45B |
Volume | 44,509,671 | 3,323,243 |
Sector | Industrials | Health |
52-Week High | $19.19 | $70.59 |
52-Week Low | $1.95 | $9.03 |
Typical Hold Time | 17 Days | 0 Days |
Enterprise Value | $1.04B | $707.46M |
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $2.32, down 2.93% today, with bearish technical signals from moving averages despite oversold RSI readings. The company shows explosive revenue growth (from $114M in 2025 to $214M in 2026) but remains deeply unprofitable with negative gross margins and net losses. Recent catalysts include a $87M DOE loan advance and a Google partnership for a West Virginia energy project, driving positive media coverage.
The stock presents high-risk speculation with Wall Street analysts maintaining a cautious 'Hold' consensus (63.64%) despite a $7.10 price target implying 206% upside. Investment appeal hinges on EOSE scaling production and achieving profitability, but substantial execution risks and cash burn require careful monitoring. Current valuation at 4.46x sales appears stretched given persistent losses.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →